Abbott (ABT) Q3 2026 Financial Results Summary
QuoteReporter
Abbott (ABT) Q3 2026: Strong Sales Growth, EPS Guidance Tightened — Positive Outlook
Abbott reported a robust third quarter for 2026, with reported sales growth of $1.9 billion or +14.5% YoY. This performance reflects a solid demand across its diverse product portfolio, particularly in the diagnostics and medical devices segments.
Key Financial Metrics
- Total Sales: $13.3 billion, up from $11.3 billion in Q3 2025.
- GAAP Diluted EPS: $0.53, down from $0.94 in Q3 2025, a decrease of -43.6%.
- Adjusted Diluted EPS: $1.42, up from $1.30 in Q3 2025, an increase of +9.2%.
- Comparable Sales Growth: 7.0%.
Analyst View
This quarter can be viewed positively for shareholders despite the decline in GAAP EPS. The adjusted EPS growth indicates that Abbott is effectively managing its operational costs and benefiting from its strategic investments. The strong sales growth of 14.5% demonstrates robust demand, particularly in the diagnostics segment, which saw a staggering 46.7% increase in sales. This performance is encouraging, especially as Abbott reaffirms its full-year adjusted diluted EPS guidance range of $5.50 to $5.55.
Segment Performance
- Nutrition: Sales increased 5.1% YoY, driven by a 7.9% increase in the U.S. market.
- Diagnostics: Sales surged 46.7% YoY, with comparable sales growth of 6.4%.
- Established Pharmaceuticals: Reported a 6.8% increase in sales.
- Medical Devices: Sales grew 6.9% YoY, with notable growth in Electrophysiology and Rhythm Management.
Dividend and Guidance
Abbott declared its 411th consecutive quarterly dividend of $0.63 per share, payable on November 16, 2026. This consistent dividend payout underscores Abbott's commitment to returning value to shareholders.
The company has also tightened its full-year 2026 adjusted diluted EPS guidance to a range of $5.50 to $5.55, projecting a comparable sales growth of approximately 6.0% for the full year.
Forward Catalyst
Investors should closely monitor Abbott's upcoming product launches and regulatory approvals, particularly in the diagnostics and medical devices segments. The recent FDA approvals for innovative products like the Libre® Duo and TactiFlex™ Duo Ablation Catheter could drive future growth. Additionally, the performance of the newly launched Similac® 360 Total Care® Made With Whole Milk infant formula will be crucial in assessing the nutrition segment's trajectory.
In summary, while the decline in GAAP EPS may raise concerns, the overall growth in sales and adjusted EPS, coupled with a strong product pipeline, positions Abbott favorably for the future.
Condensed Consolidated Statement of Earnings
Note: All amounts are in millions.
| 3Q26 | 3Q25 | % Change |
|---|---|---|
| $13,3… | $11,3… | 14.5 |
| 5,628 | 5,075 | 10.9 |
| 841 | 420 | n/m |
| 920 | 766 | 20.1 |
| 4,266 | 3,051 | 39.8 |
| 11,655 | 9,312 | 25.2 |
| 1,358 | 2,057 | -34.0 |
| 297 | 44 | n/m |
| -6 | -17 | n/m |
| -164 | -150 | 9.4 |
| 1,231 | 2,180 | -43.5 |
| 311 | 536 | -42.0 |
| $920 | $1,644 | -44.1 |
| $2,4… | $2,278 | 8.7 |
| $0.53 | $0.94 | -43.6 |
| $1.42 | $1.30 | 9.2 |
| 1,738 | 1,749 |
Condensed Consolidated Balance Sheets
Note: All amounts are in millions.
| Sept. 30, 2026 | Dec. 31, 2025 |
|---|---|
| $5,348 | $7,241 |
| 5,421 | 4,572 |
| 4,198 | 3,814 |
| 1,330 | 895 |
| 16,297 | 16,522 |
| 5,168 | 5,045 |
| 27,437 | 26,486 |
| 14,096 | 15,088 |
| 2,439 | 2,084 |
| 65,437 | 65,225 |
| 1,044 | 1,259 |
| 5,629 | 5,311 |
| 4,882 | 4,225 |
| 11,555 | 10,795 |
| 22,363 | 21,136 |
| 3,102 | 3,123 |
| 4,564 | 5,380 |
| 41,584 | 40,434 |
| 23,853 | 24,791 |
| 1,000 | 1,000 |
| 24,853 | 25,791 |
| 65,437 | 65,225 |
Disclaimer
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.
